---
document_datetime: 2025-12-29 14:34:47
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/olazax.html
document_name: olazax.html
version: success
processing_time: 0.1260936
conversion_datetime: 2025-12-30 21:11:31.520828
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Olazax

[RSS](/en/individual-human-medicine.xml/65921)

##### Authorised

This medicine is authorised for use in the European Union

olanzapine Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Olazax](#more-information-on-olazax-1145)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis for the CHMP recommendations, read the scientific discussion (also part of the EPAR).

Expand section

Collapse section

## What is Olazax?

Olazax is a medicine containing the active substance olanzapine. It is available as tablets (5, 7.5 10, 15 and 20 mg).

## What is Olazax used for?

Olazax is used to treat adults with schizophrenia. Schizophrenia is a mental illness that has a number of symptoms, including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (mistaken beliefs). Olazax is also effective in maintaining improvement in patients who have responded to an initial course of treatment.

Olazax is also used to treat moderate to severe manic episodes (extremely high mood) in adults. It can also be used to prevent the recurrence of these episodes (when symptoms come back) in adults with bipolar disorder (a mental illness with alternating periods of high mood and depression) who have responded to an initial course of treatment.

The medicine can only be obtained with a prescription.

## How is Olazax used?

The recommended starting dose of Olazax depends on the disease being treated: 10 mg per day is used in schizophrenia and in the prevention of manic episodes, and 15 mg per day in the treatment of manic episodes, unless it is used with other medicines, in which case the starting dose can be 10 mg per day. The dose is adjusted according to how well the patient responds to and tolerates the treatment. The usual dose range is between 5 and 20 mg per day. Patients over 65 years of age and patients who have reduced liver or kidney function may need a lower starting dose of 5 mg per day.

## How does Olazax work?

The active substance in Olazax, olanzapine, is an antipsychotic medicine. It is known as an 'atypical' antipsychotic because it is different from the older antipsychotic medicines that have been available since the 1950s. Its exact mechanism of action is unknown, but it attaches to several different receptors on the surface of nerve cells in the brain. This disrupts signals transmitted between brain cells by 'neurotransmitters', chemicals that allow nerve cells to communicate with each other. It is thought that olanzapine's beneficial effect is due to it blocking receptors for the neurotransmitters 5?hydroxytrypamine (also called serotonin) and dopamine. Since these neurotransmitters are involved in schizophrenia and in bipolar disorder, olanzapine helps to normalise the activity of the brain, reducing the symptoms of these diseases.

## How has Olazax been studied?

Because Olazax is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Zyprexa. Medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefit and risk of Olazax?

Because Olazax is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine.

## Why has Olazax been approved?

The CHMP concluded that, in accordance with EU requirements, Olazax has been shown to have comparable quality and to be bioequivalent to Zyprexa. Therefore, the CHMP's view was that, as for Zyprexa, the benefit outweighs the identified risk. The Committee recommended that Olazax be given marketing authorisation.

## Other information about Olazax

The European Commission granted a marketing authorisation valid throughout the EU for Olazax on 11 December 2009.

For more information about treatment with Olazax, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Olazax : EPAR - Summary for the public

English (EN) (72.12 KB - PDF)

**First published:** 29/01/2010

**Last updated:** 15/09/2014

[View](/en/documents/overview/olazax-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-861)

български (BG) (133.57 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

15/09/2014

[View](/bg/documents/overview/olazax-epar-summary-public_bg.pdf)

español (ES) (120.58 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

15/09/2014

[View](/es/documents/overview/olazax-epar-summary-public_es.pdf)

čeština (CS) (122.06 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

15/09/2014

[View](/cs/documents/overview/olazax-epar-summary-public_cs.pdf)

dansk (DA) (130.4 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

15/09/2014

[View](/da/documents/overview/olazax-epar-summary-public_da.pdf)

Deutsch (DE) (121.73 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

15/09/2014

[View](/de/documents/overview/olazax-epar-summary-public_de.pdf)

eesti keel (ET) (117.61 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

15/09/2014

[View](/et/documents/overview/olazax-epar-summary-public_et.pdf)

ελληνικά (EL) (130.53 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

15/09/2014

[View](/el/documents/overview/olazax-epar-summary-public_el.pdf)

français (FR) (132.64 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

15/09/2014

[View](/fr/documents/overview/olazax-epar-summary-public_fr.pdf)

hrvatski (HR) (121.05 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

15/09/2014

[View](/hr/documents/overview/olazax-epar-summary-public_hr.pdf)

italiano (IT) (118.95 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

15/09/2014

[View](/it/documents/overview/olazax-epar-summary-public_it.pdf)

latviešu valoda (LV) (132.5 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

15/09/2014

[View](/lv/documents/overview/olazax-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (130.42 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

15/09/2014

[View](/lt/documents/overview/olazax-epar-summary-public_lt.pdf)

magyar (HU) (125.46 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

15/09/2014

[View](/hu/documents/overview/olazax-epar-summary-public_hu.pdf)

Malti (MT) (136.78 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

15/09/2014

[View](/mt/documents/overview/olazax-epar-summary-public_mt.pdf)

Nederlands (NL) (120.07 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

15/09/2014

[View](/nl/documents/overview/olazax-epar-summary-public_nl.pdf)

polski (PL) (130.01 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

15/09/2014

[View](/pl/documents/overview/olazax-epar-summary-public_pl.pdf)

português (PT) (120.01 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

15/09/2014

[View](/pt/documents/overview/olazax-epar-summary-public_pt.pdf)

română (RO) (94.05 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

15/09/2014

[View](/ro/documents/overview/olazax-epar-summary-public_ro.pdf)

slovenčina (SK) (122.65 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

15/09/2014

[View](/sk/documents/overview/olazax-epar-summary-public_sk.pdf)

slovenščina (SL) (119.67 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

15/09/2014

[View](/sl/documents/overview/olazax-epar-summary-public_sl.pdf)

Suomi (FI) (118.86 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

15/09/2014

[View](/fi/documents/overview/olazax-epar-summary-public_fi.pdf)

svenska (SV) (122.63 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

15/09/2014

[View](/sv/documents/overview/olazax-epar-summary-public_sv.pdf)

## Product information

Olazax : EPAR - Product Information

English (EN) (887.9 KB - PDF)

**First published:** 29/01/2010

**Last updated:** 31/07/2020

[View](/en/documents/product-information/olazax-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-845)

български (BG) (1.4 MB - PDF)

**First published:**

29/01/2010

**Last updated:**

31/07/2020

[View](/bg/documents/product-information/olazax-epar-product-information_bg.pdf)

español (ES) (1.05 MB - PDF)

**First published:**

29/01/2010

**Last updated:**

31/07/2020

[View](/es/documents/product-information/olazax-epar-product-information_es.pdf)

čeština (CS) (1.02 MB - PDF)

**First published:**

29/01/2010

**Last updated:**

31/07/2020

[View](/cs/documents/product-information/olazax-epar-product-information_cs.pdf)

dansk (DA) (869.88 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

31/07/2020

[View](/da/documents/product-information/olazax-epar-product-information_da.pdf)

Deutsch (DE) (1.19 MB - PDF)

**First published:**

29/01/2010

**Last updated:**

31/07/2020

[View](/de/documents/product-information/olazax-epar-product-information_de.pdf)

eesti keel (ET) (921.38 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

31/07/2020

[View](/et/documents/product-information/olazax-epar-product-information_et.pdf)

ελληνικά (EL) (1.05 MB - PDF)

**First published:**

29/01/2010

**Last updated:**

31/07/2020

[View](/el/documents/product-information/olazax-epar-product-information_el.pdf)

français (FR) (1.14 MB - PDF)

**First published:**

29/01/2010

**Last updated:**

31/07/2020

[View](/fr/documents/product-information/olazax-epar-product-information_fr.pdf)

hrvatski (HR) (1021.3 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

31/07/2020

[View](/hr/documents/product-information/olazax-epar-product-information_hr.pdf)

íslenska (IS) (820.83 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

31/07/2020

[View](/is/documents/product-information/olazax-epar-product-information_is.pdf)

italiano (IT) (1.27 MB - PDF)

**First published:**

29/01/2010

**Last updated:**

31/07/2020

[View](/it/documents/product-information/olazax-epar-product-information_it.pdf)

latviešu valoda (LV) (1 MB - PDF)

**First published:**

29/01/2010

**Last updated:**

31/07/2020

[View](/lv/documents/product-information/olazax-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1007.55 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

31/07/2020

[View](/lt/documents/product-information/olazax-epar-product-information_lt.pdf)

magyar (HU) (1.28 MB - PDF)

**First published:**

29/01/2010

**Last updated:**

31/07/2020

[View](/hu/documents/product-information/olazax-epar-product-information_hu.pdf)

Malti (MT) (1.17 MB - PDF)

**First published:**

29/01/2010

**Last updated:**

31/07/2020

[View](/mt/documents/product-information/olazax-epar-product-information_mt.pdf)

Nederlands (NL) (1.01 MB - PDF)

**First published:**

29/01/2010

**Last updated:**

31/07/2020

[View](/nl/documents/product-information/olazax-epar-product-information_nl.pdf)

norsk (NO) (1022.01 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

31/07/2020

[View](/no/documents/product-information/olazax-epar-product-information_no.pdf)

polski (PL) (1.41 MB - PDF)

**First published:**

29/01/2010

**Last updated:**

31/07/2020

[View](/pl/documents/product-information/olazax-epar-product-information_pl.pdf)

português (PT) (1.08 MB - PDF)

**First published:**

29/01/2010

**Last updated:**

31/07/2020

[View](/pt/documents/product-information/olazax-epar-product-information_pt.pdf)

română (RO) (1.2 MB - PDF)

**First published:**

29/01/2010

**Last updated:**

31/07/2020

[View](/ro/documents/product-information/olazax-epar-product-information_ro.pdf)

slovenčina (SK) (1.62 MB - PDF)

**First published:**

29/01/2010

**Last updated:**

31/07/2020

[View](/sk/documents/product-information/olazax-epar-product-information_sk.pdf)

slovenščina (SL) (1.04 MB - PDF)

**First published:**

29/01/2010

**Last updated:**

31/07/2020

[View](/sl/documents/product-information/olazax-epar-product-information_sl.pdf)

Suomi (FI) (1.04 MB - PDF)

**First published:**

29/01/2010

**Last updated:**

31/07/2020

[View](/fi/documents/product-information/olazax-epar-product-information_fi.pdf)

svenska (SV) (770.34 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

31/07/2020

[View](/sv/documents/product-information/olazax-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** WS/1831 25/06/2020

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Olazax : EPAR - All Authorised presentations

English (EN) (21.28 KB - PDF)

**First published:** 29/01/2010

**Last updated:** 19/04/2017

[View](/en/documents/all-authorised-presentations/olazax-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-224)

български (BG) (76.33 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

19/04/2017

[View](/bg/documents/all-authorised-presentations/olazax-epar-all-authorised-presentations_bg.pdf)

español (ES) (36.08 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

19/04/2017

[View](/es/documents/all-authorised-presentations/olazax-epar-all-authorised-presentations_es.pdf)

čeština (CS) (48.27 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

19/04/2017

[View](/cs/documents/all-authorised-presentations/olazax-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (36.69 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

19/04/2017

[View](/da/documents/all-authorised-presentations/olazax-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (37.68 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

19/04/2017

[View](/de/documents/all-authorised-presentations/olazax-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (35.22 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

19/04/2017

[View](/et/documents/all-authorised-presentations/olazax-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (73.26 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

19/04/2017

[View](/el/documents/all-authorised-presentations/olazax-epar-all-authorised-presentations_el.pdf)

français (FR) (35.96 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

19/04/2017

[View](/fr/documents/all-authorised-presentations/olazax-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (29.36 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

19/04/2017

[View](/hr/documents/all-authorised-presentations/olazax-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (22.73 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

19/04/2017

[View](/is/documents/all-authorised-presentations/olazax-epar-all-authorised-presentations_is.pdf)

italiano (IT) (36.74 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

19/04/2017

[View](/it/documents/all-authorised-presentations/olazax-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (63.5 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

19/04/2017

[View](/lv/documents/all-authorised-presentations/olazax-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (65.86 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

19/04/2017

[View](/lt/documents/all-authorised-presentations/olazax-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (48.76 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

19/04/2017

[View](/hu/documents/all-authorised-presentations/olazax-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (65.03 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

19/04/2017

[View](/mt/documents/all-authorised-presentations/olazax-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (37.36 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

19/04/2017

[View](/nl/documents/all-authorised-presentations/olazax-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (22.07 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

19/04/2017

[View](/no/documents/all-authorised-presentations/olazax-epar-all-authorised-presentations_no.pdf)

polski (PL) (49.62 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

19/04/2017

[View](/pl/documents/all-authorised-presentations/olazax-epar-all-authorised-presentations_pl.pdf)

português (PT) (36.55 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

19/04/2017

[View](/pt/documents/all-authorised-presentations/olazax-epar-all-authorised-presentations_pt.pdf)

română (RO) (64.96 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

19/04/2017

[View](/ro/documents/all-authorised-presentations/olazax-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (48.86 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

19/04/2017

[View](/sk/documents/all-authorised-presentations/olazax-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (35.94 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

19/04/2017

[View](/sl/documents/all-authorised-presentations/olazax-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (36.87 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

19/04/2017

[View](/fi/documents/all-authorised-presentations/olazax-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (36.86 KB - PDF)

**First published:**

29/01/2010

**Last updated:**

19/04/2017

[View](/sv/documents/all-authorised-presentations/olazax-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Olazax Active substance olanzapine International non-proprietary name (INN) or common name olanzapine Therapeutic area (MeSH)

- Schizophrenia
- Bipolar Disorder

Anatomical therapeutic chemical (ATC) code N05AH03

### Pharmacotherapeutic group

Psycholeptics

### Therapeutic indication

**Adults**

Olanzapine is indicated for the treatment of schizophrenia.

Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.

Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.

## Authorisation details

EMA product number EMEA/H/C/001087

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Glenmark Pharmaceuticals s.r.o.

Glenmark Pharmaceuticals s.r.o.

Marketing authorisation issued 11/12/2009 Revision 12

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Olazax : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (166.6 KB - PDF)

**First published:** 27/05/2010

**Last updated:** 31/07/2020

[View](/en/documents/procedural-steps-after/olazax-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Olazax : EPAR - Public assessment report

English (EN) (200.23 KB - PDF)

**First published:** 29/01/2010

**Last updated:** 29/01/2010

[View](/en/documents/assessment-report/olazax-epar-public-assessment-report_en.pdf)

#### More information on Olazax

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-573)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 31/07/2020

## Share this page

[Back to top](#main-content)